GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » Scaled Net Operating Assets

GlobeImmune (GlobeImmune) Scaled Net Operating Assets : -0.57 (As of Mar. 2016)


View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

GlobeImmune's operating assets for the quarter that ended in Mar. 2016 was $1.08 Mil. GlobeImmune's operating liabilities for the quarter that ended in Mar. 2016 was $7.62 Mil. GlobeImmune's Total Assets for the quarter that ended in Dec. 2015 was $11.51 Mil. Therefore, GlobeImmune's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2016 was -0.57.


GlobeImmune Scaled Net Operating Assets Historical Data

The historical data trend for GlobeImmune's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeImmune Scaled Net Operating Assets Chart

GlobeImmune Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Scaled Net Operating Assets
Get a 7-Day Free Trial -8.35 -11.17 -48.35 -1.51 -0.38

GlobeImmune Quarterly Data
Dec10 Mar11 Jun11 Dec11 Mar12 Jun12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.62 -0.56 -0.52 -0.57

Competitive Comparison of GlobeImmune's Scaled Net Operating Assets

For the Biotechnology subindustry, GlobeImmune's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlobeImmune's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeImmune's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where GlobeImmune's Scaled Net Operating Assets falls into.



GlobeImmune Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

GlobeImmune's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2015 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2015 )
=(Operating Assets (A: Dec. 2015 )-Operating Liabilities (A: Dec. 2015 ))/Total Assets (A: Dec. 2014 )
=(1.605-8.518)/18.368
=-0.38

where

Operating Assets(A: Dec. 2015 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=11.506 - 9.901
=1.605

Operating Liabilities(A: Dec. 2015 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.518 - 0 - 0
=8.518

GlobeImmune's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2016 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2016 )
=(Operating Assets (Q: Mar. 2016 )-Operating Liabilities (Q: Mar. 2016 ))/Total Assets (Q: Dec. 2015 )
=(1.077-7.621)/11.506
=-0.57

where

Operating Assets(Q: Mar. 2016 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=9.771 - 8.694
=1.077

Operating Liabilities(Q: Mar. 2016 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=7.621 - 0 - 0
=7.621

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlobeImmune Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of GlobeImmune's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


GlobeImmune (GlobeImmune) Business Description

Traded in Other Exchanges
N/A
Address
1450 Infinite Drive, Louisville, CO, USA, 80027
GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Executives
Augustine Lawlor director 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell director
S. Edward Torres director C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh other: Former 10% Owner 265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner other: Former 10% Owner C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli other: Former 10% Owner 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p. other: Former 10% Owner 44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag director
Rodell Timothy C Jr director, officer: CEO & Pres 201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp 10 percent owner 50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines